CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

ανά Meyer, Sara C., Keller, Matthew D., Chiu, Sophia, Koppikar, Priya, Guryanova, Olga A., Rapaport, Franck, Xu, Ke, Manova, Katia, Pankov, Dmitry, O’Reilly, Richard J., Kleppe, Maria, McKenney, Anna Sophia, Shih, Alan H., Shank, Kaitlyn, Ahn, Jihae, Papalexi, Eftymia, Spitzer, Barbara, Socci, Nick, Viale, Agnes, Mandon, Emeline, Ebel, Nicolas, Andraos, Rita, Rubert, Joëlle, Dammassa, Ernesta, Romanet, Vincent, Dölemeyer, Arno, Zender, Michael, Heinlein, Melanie, Rampal, Rajit, Weinberg, Rona Singer, Hoffman, Ron, Sellers, William R., Hofmann, Francesco, Murakami, Masato, Baffert, Fabienne, Gaul, Christoph, Radimerski, Thomas, Levine, Ross L.
Τόπος έκδοσης Cancer Cell (2015)